» Articles » PMID: 37740179

Transcriptional Landscape of Kaposi Sarcoma Tumors Identifies Unique Immunologic Signatures and Key Determinants of Angiogenesis

Abstract

Background: Kaposi sarcoma (KS) is a multicentric tumor caused by Kaposi sarcoma herpesvirus (KSHV) that leads to morbidity and mortality among people with HIV worldwide. KS commonly involves the skin but can occur in the gastrointestinal tract (GI) in severe cases.

Methods: RNA sequencing was used to compare the cellular and KSHV gene expression signatures of skin and GI KS lesions in 44 paired samples from 19 participants with KS alone or with concurrent KSHV-associated diseases. Analyses of KSHV expression from KS lesions identified transcriptionally active areas of the viral genome.

Results: The transcript of an essential viral lytic gene, ORF75, was detected in 91% of KS lesions. Analyses of host genes identified 370 differentially expressed genes (DEGs) unique to skin KS and 58 DEGs unique to GI KS lesions as compared to normal tissue. Interleukin (IL)-6 and IL-10 gene expression were higher in skin lesions as compared to normal skin but not in GI KS lesions. Twenty-six cellular genes were differentially expressed in both skin and GI KS tissues: these included Fms-related tyrosine kinase 4 (FLT4), encoding an angiogenic receptor, and Stanniocalcin 1 (STC1), a secreted glycoprotein. FLT4 and STC1 were further investigated in functional studies using primary lymphatic endothelial cells (LECs). In these models, KSHV infection of LECs led to increased tubule formation that was impaired upon knock-down of STC1 or FLT4.

Conclusions: This study of transcriptional profiling of KS tissue provides novel insights into the characteristics and pathogenesis of this unique virus-driven neoplasm.

Citing Articles

Exploration of RNA-binding proteins identified RPS27 as a potential regulator associated with Kaposi's sarcoma development.

Zhang J, Wang P, Li T, Luo D, Qu Y, Ding Y BMC Cancer. 2025; 25(1):362.

PMID: 40016701 PMC: 11866810. DOI: 10.1186/s12885-025-13790-0.


Transcriptomic Profiling and Tumor Microenvironment Classification Reveal Unique and Dynamic Immune Biology in HIV-Associated Kaposi Sarcoma.

Yang J, Cali Daylan A, Shevkoplias A, Postovalova E, Wang M, Tyshevich A Cells. 2025; 14(2).

PMID: 39851562 PMC: 11764145. DOI: 10.3390/cells14020134.


Analysis of tumor infiltrating immune cells in Kaposi sarcoma lesions discovers shifts in macrophage populations.

Tagawa T, Mahesh G, Ziegelbauer J Glob Health Med. 2024; 6(5):310-315.

PMID: 39483448 PMC: 11514630. DOI: 10.35772/ghm.2024.01066.


Mapping herpesvirus-driven impacts on the cellular milieu and transcriptional profile of Kaposi sarcoma in patient-derived mouse models.

Li X, Ohler Z, Day A, Bassel L, Grosskopf A, Afsari B bioRxiv. 2024; .

PMID: 39386738 PMC: 11463583. DOI: 10.1101/2024.09.27.615429.


HIV-associated cancers and lymphoproliferative disorders caused by Kaposi sarcoma herpesvirus and Epstein-Barr virus.

Lurain K, Ramaswami R, Krug L, Whitby D, Ziegelbauer J, Wang H Clin Microbiol Rev. 2024; 37(3):e0002223.

PMID: 38899877 PMC: 11391709. DOI: 10.1128/cmr.00022-23.


References
1.
Jacobs S, Damania B . The viral interferon regulatory factors of KSHV: immunosuppressors or oncogenes?. Front Immunol. 2012; 2:19. PMC: 3342017. DOI: 10.3389/fimmu.2011.00019. View

2.
Ramaswami R, Lurain K, Marshall V, Rupert A, Labo N, Cornejo-Castro E . Elevated IL-13 in effusions of patients with HIV and primary effusion lymphoma as compared with other Kaposi sarcoma herpesvirus-associated disorders. AIDS. 2020; 35(1):53-62. PMC: 7856311. DOI: 10.1097/QAD.0000000000002692. View

3.
Arnaoutova I, Kleinman H . In vitro angiogenesis: endothelial cell tube formation on gelled basement membrane extract. Nat Protoc. 2010; 5(4):628-35. DOI: 10.1038/nprot.2010.6. View

4.
Lurain K, Ramaswami R, Yarchoan R, Uldrick T . Anti-PD-1 and Anti-PD-L1 Monoclonal Antibodies in People Living with HIV and Cancer. Curr HIV/AIDS Rep. 2020; 17(5):547-556. PMC: 7799392. DOI: 10.1007/s11904-020-00525-y. View

5.
Ramaswami R, Lurain K, Polizzotto M, Ekwede I, Waldon K, Steinberg S . Characteristics and outcomes of KSHV-associated multicentric Castleman disease with or without other KSHV diseases. Blood Adv. 2021; 5(6):1660-1670. PMC: 7993110. DOI: 10.1182/bloodadvances.2020004058. View